Evidence map›Paper›PMID 31469826›Full record

ArticlePLoS genetics2019

A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene.

Cavin Wong, Fei Chen, Najmeh Alirezaie, Yifan Wang, Adeline Cuggia, Ayelet Borgida, Spring Holter, Tatiana Lenko, Celine Domecq, Alzheimer’s Disease Neuroimaging Initiative and 14 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020
    Review
  10. Article
  11. Identification of NovelFrontiers in genetics · 2020
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 10 institutions in 2 countries.

Cavin WongThe Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.ORCID 0000-0002-6833-9559
Fei ChenJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID 0000-0002-1679-9932
Najmeh AlirezaieMcGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
Yifan WangThe Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Adeline CuggiaThe Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.ORCID 0000-0002-0316-0320
Ayelet BorgidaLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Spring HolterLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Tatiana LenkoThe Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.ORCID 0000-0002-7186-2498
Celine DomecqThe Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Alzheimer’s Disease Neuroimaging Initiative
Gloria M PetersenDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Sapna SyngalDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Gastroenterology Division, Brigham and Women's Hospital, Harvard Medical Schozol, Boston, Massachusetts, United States of America.ORCID 0000-0001-5487-7471
Randall BrandDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Anil K RustgiDivision of Gastroenterology, Departments of Medicine and Genetics, Pancreatic Cancer Translation Center of Excellence, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-5877-7993
Michele L CoteKarmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, United States of America.
Elena StoffelDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
Sara H OlsonDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Nicholas J RobertsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States of America.
Mohammad R AkbariWomen's College Hospital Research Institute, Women's College Hospital, Toronto, Ontario, Canada.ORCID 0000-0002-8851-3614
Jacek MajewskiMcGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
Alison P KleinSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States of America.
Celia M T GreenwoodLudmer Centre for Neuroinformatics & Mental Health, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-2427-5696
Steven GallingerLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
George ZogopoulosThe Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
McGill University Health Centre · CAJohns Hopkins University · USMount Sinai Hospital · CABrigham and Women's Hospital · USMemorial Sloan Kettering Cancer Center · USWayne State University · USMayo Clinic in Florida · USMcGill University and Génome Québec Innovation Centre · CAUniversity of Pittsburgh · USUniversity of Toronto · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7M
Pancreatic Cancer Genetic Epidemiology Consortium (PACGENE)R01CA097075 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2002 to 2012
$15.8M
Validation and Fine-Scale Mapping of Pancreatic Cancer Susceptibility Loci (Study)R01CA154823 · NCI · JOHNS HOPKINS UNIVERSITY · PI KLEIN, ALISON P · 2011 to 2020
$5.7M
Role of Vav1 protooncogene in pancreatic cancerP20CA102701 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI PETERSEN, GLORIA M. · 2003 to 2003
$1.5M
Integrative Analyses to Identify Pancreatic Cancer Susceptibility GenesK99CA190889 · NCI · JOHNS HOPKINS UNIVERSITY · PI ROBERTS, NICHOLAS JASON · 2015 to 2016
$172k
NCI NIH HHS K99 CA190889NCI NIH HHS P20 CA102701NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA062924NCI NIH HHS P50 CA102701NCI NIH HHS R01 CA097075NCI NIH HHS R01 CA154823NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

Pancreatic adenocarcinoma (PC) is a lethal malignancy that is familial or associated with genetic syndromes in 10% of cases. Gene-based surveillance strategies for at-risk individuals may improve clinical outcomes. However, familial PC (FPC) is plagued by genetic heterogeneity and the genetic basis for the majority of FPC remains elusive, hampering the development of gene-based surveillance programs. The study was powered to identify genes with a cumulative pathogenic variant prevalence of at least 3%, which includes the most prevalent PC susceptibility gene, BRCA2. Since the majority of known PC susceptibility genes are involved in DNA repair, we focused on genes implicated in these pathways. We performed a region-based association study using the Mixed-Effects Score Test, followed by leave-one-out characterization of PC-associated gene regions and variants to identify the genes and variants driving risk associations. We evaluated 398 cases from two case series and 987 controls without a personal history of cancer. The first case series consisted of 109 patients with either FPC (n = 101) or PC at ≤50 years of age (n = 8). The second case series was composed of 289 unselected PC cases. We validated this discovery strategy by identifying known pathogenic BRCA2 variants, and also identified SMG1, encoding a serine/threonine protein kinase, to be significantly associated with PC following correction for multiple testing (p = 3.22x10-7). The SMG1 association was validated in a second independent series of 532 FPC cases and 753 controls (p<0.0062, OR = 1.88, 95%CI 1.17-3.03). We showed segregation of the c.4249A>G SMG1 variant in 3 affected relatives in a FPC kindred, and we found c.103G>A to be a recurrent SMG1 variant associating with PC in both the discovery and validation series. These results suggest that SMG1 is a novel PC susceptibility gene, and we identified specific SMG1 gene variants associated with PC risk.

Indexed as

AdenocarcinomaAdultBRCA2 ProteinCarcinomaFemaleGenes, BRCA2Genetic Association StudiesGenetic Predisposition to DiseaseGerm-Line MutationHumansMaleMiddle AgedPancreasPancreatic NeoplasmsProtein Serine-Threonine KinasesSequence Analysis, DNABRCA2 ProteinBRCA2 protein, humanProtein Serine-Threonine KinasesSMG1 protein, human

Identifiers

PMID31469826
PMCPMC6742418
OpenAlexW2970158193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.